Schwab Network on $LLY (Oct 29, 2026)
LLY's quarter was very strong and exceeded expectations, with adjusted EPS $7.48 vs $6.50 expected and revenue $24.4 billion vs $22.6 billion expected, and guidance raised. Its two main GLP-1 drugs both beat estimates and are about two-thirds of quarterly revenue, showing dependence; obesity pills have not arrived, a minor weakness offset by those drugs.
Jump to any passage
last but not least, there is some really great news for Eli Lilly, and the GLP -1 drug is still part of the story as well. Yes, they are winning the weight-loss battles for Eli Lilly, and these stocks are taking off again with gains of more than 7 % on the back of their quarterly results.
Very strong results that exceeded expectations; Earnings of $7.48 per share on an adjusted basis versus the $6.50 expected by the market, and revenue of $24.4 billion versus the $22.6 billion expected by the market.
So it was a quarter that exceeded expectations with the guidance raised.
It's all about Mongaroo and Zipawnd. They are doing the hard work, no pun intended here. Mongaro earned $10.72 billion . This represents a 65% increase over last year. Zibound generated $5.35 billion .
This represents a 49% increase, and both exceeded analysts' estimates. They together account for about two-thirds of Eli Lilly's quarterly revenue. Therefore, the strength there also shows a dependence on this product .
Regarding forecasts, Eli Lilly now expects annual revenues of between $91 billion and $92 billion . This is an increase in expectations. Their guidance for adjusted earnings is between $35 and $36 per share.
There are some comments about expanding access through Medicare coverage. As for the obesity treatment pills, they have not arrived yet . This is a minor weakness, but they are clearly generating enough revenue from Zybound and Mongaro to offset this new drug. Nicole?
What this channel has said about $LLY
Schwab Network has 4 calls on this stock; only the adjacent ones are shown.